A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA

[1]  S. Peroutka,et al.  Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[2]  M. Geyer,et al.  Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. , 1988, The Journal of pharmacology and experimental therapeutics.

[3]  G. Hanson,et al.  Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. , 1988, The Journal of pharmacology and experimental therapeutics.

[4]  E. D. De Souza,et al.  Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. , 1988, European journal of pharmacology.

[5]  B. Yamamoto,et al.  The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. , 1988, European journal of pharmacology.

[6]  G. Koob,et al.  Methysergide potentiates the hyperactivity produced by MDMA in rats , 1988, Pharmacology Biochemistry and Behavior.

[7]  R. Glennon,et al.  Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs , 1988, Pharmacology Biochemistry and Behavior.

[8]  D. M. Barnes.  New data intensify the agony over ecstasy. , 1988, Science.

[9]  Peroutka Sj.  Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. , 1987 .

[10]  E. D. De Souza,et al.  3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.

[11]  T. Steele,et al.  Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. , 1987, Biochemical pharmacology.

[12]  S. Robinson,et al.  (+/-)3,4-Methylenedioxymethamphetamine (MDMA) produces long-term reductions in brain 5-hydroxytryptamine in rats. , 1987, European journal of pharmacology.

[13]  C. J. Schmidt.  Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. , 1987, European journal of pharmacology.

[14]  L S Seiden,et al.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.

[15]  R. Bost,et al.  'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. , 1987, JAMA.

[16]  W. Lovenberg,et al.  In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. , 1987, Biochemical pharmacology.

[17]  M. P. Johnson,et al.  Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. , 1986, European journal of pharmacology.

[18]  D. E. Nichols,et al.  Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. , 1986, Journal of medicinal chemistry.

[19]  L. Harris,et al.  Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. , 1986, Drug and alcohol dependence.

[20]  J. Glowinski,et al.  Partial protection by desmethylimipramine of the mesocortical dopamine neurones from the neurotoxic effect of 6-hydroxydopamine injected in ventral mesencephalic tegmentum. The role of noradrenergic innervation , 1986, Brain Research.

[21]  P. Morgan,et al.  Designer Drug Confusion: A Focus on MDMA , 1986, Journal of drug education.

[22]  G. Hanson,et al.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. , 1986, European journal of pharmacology.

[23]  J. Bakalar,et al.  Can drugs be used to enhance the psychotherapeutic process? , 1986, American journal of psychotherapy.

[24]  N. Swerdlow,et al.  The neural substrates for the motor-activating properties of psychostimulants: A review of recent findings , 1986, Pharmacology Biochemistry and Behavior.

[25]  D. Segal,et al.  Behavioral effects of xylamine-induced depletions of brain norepinephrine: Interaction with amphetamine , 1986, Behavioural Brain Research.

[26]  T. Berger,et al.  Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: Histochemical and neurochemical analysis , 1986, Brain Research.

[27]  M. D. Schechter.  Discriminative profile of MDMA , 1986, Pharmacology Biochemistry and Behavior.

[28]  W. Lovenberg,et al.  Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. , 1986, European journal of pharmacology.

[29]  N. Swerdlow,et al.  Blockade of amphetamine but not opiate-induced locomotion following antagonism of dopamine function in the rat , 1986, Pharmacology Biochemistry and Behavior.

[30]  J. Yanai,et al.  The relative importance of dopamine and norepinephrine in mediating locomotor activity , 1983, Progress in Neurobiology.

[31]  D. E. Nichols,et al.  Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. , 1982, Journal of medicinal chemistry.

[32]  J. Glowinski,et al.  Non-dopaminergic fibres may regulate dopamine-sensitive adenylate cyclase in the prefrontal cortex and nucleus accumbens , 1982, Nature.

[33]  H. Fibiger,et al.  Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens , 1980, Pharmacology Biochemistry and Behavior.

[34]  A. Shulgin,et al.  Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). , 1980, Journal of pharmaceutical sciences.

[35]  P. Kissinger,et al.  DETERMINATION OF CATECHOLAMINES IN RAT BRAIN PARTS BY REVERSE‐PHASE ION‐PAIR LIQUID CHROMATOGRAPHY , 1978, Journal of neurochemistry.

[36]  S. Iversen,et al.  Selective 60HDA-induced destruction of mesolimbic dopamine neurons: Abolition of psychostimulant-induced locomotor activity in rats , 1976 .

[37]  M. Palkovits,et al.  Regional concentrations of noradrenaline and dopamine in rat brain , 1976, Brain Research.

[38]  B. Cooper,et al.  An inhibitory role for brain serotonin-containing systems in the locomotor effects of d-amphetamine. , 1976, The Journal of pharmacology and experimental therapeutics.

[39]  D. Segal,et al.  Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways , 1976, Brain Research.

[40]  B. K. Hartman,et al.  The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine‐B‐hydroxylase as a marker , 1975, The Journal of comparative neurology.

[41]  S. Iversen,et al.  Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum , 1975, Brain Research.

[42]  H. Fibiger,et al.  Ascending catecholamine pathways and amphetamine-induced locomotor activity: Importance of dopamine and apparent non-involvement of norepinephrine , 1975, Brain Research.

[43]  S. Iversen,et al.  The pharmacological and anatomical substrates of the amphetamine response in the rat , 1975, Brain Research.

[44]  K. E. Moore,et al.  The relative importance of dopaminergic and noradrenergic neuronal systems for the stimulation of locomotor activity induced by amphetamine and other drugs. , 1973, Neuropharmacology.

[45]  F. Bloom,et al.  Lesions of Central Norepinephrine Terminals with 6-OH-Dopamine: Biochemistry and Fine Structure , 1969, Science.

[46]  H. Fibiger,et al.  Anatomical analysis of the involvement of mesolimbocortical dopamine in the locomotor stimulant actions ofd-amphetamine and apomorphine , 2005, Psychopharmacology.

[47]  G. Koob,et al.  Amphetamine-, scopolamine- and caffeine-induced locomotor activity following 6-hydroxydopamine lesions of the mesolimbic dopamine system , 2004, Psychopharmacology.

[48]  C. Kornetsky,et al.  The threshold lowering effects of MDMA (ecstasy) on brain-stimulation reward , 2004, Psychopharmacology.

[49]  R. Griffiths,et al.  Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon , 2004, Psychopharmacology.

[50]  F. Bloom,et al.  Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats , 2004, Psychopharmacology.

[51]  R. Oberlender,et al.  Drug discrimination studies with MDMA and amphetamine , 2004, Psychopharmacology.

[52]  S. Peroutka.  Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. , 1987, The New England journal of medicine.

[53]  C. J. Schmidt,et al.  Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. , 1987, The Journal of pharmacology and experimental therapeutics.

[54]  T. Alexander,et al.  CHARACTERIZATION OF THREE NEW PSYCHOTOMIMETICS , 1978 .

[55]  S. Iversen,et al.  Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. , 1976, European journal of pharmacology.

[56]  C. Sachs,et al.  Mechanisms of action of 6-hydroxydopamine. , 1975, Biochemical pharmacology.